Tau368 improves p-tau diagnostic accuracy for FTLD-tau from FTLD-TDP - Summary - MDSpire

Tau368 improves p-tau diagnostic accuracy for FTLD-tau from FTLD-TDP

  • By

  • Przemysław R. Kac

  • Katheryn A. Q. Cousins

  • Alicja Szadziewska

  • Leslie M. Shaw

  • Michael Turton

  • Vivianna M. Van Deerlin

  • Peter Harrison

  • Henrik Zetterberg

  • David A. Wolk

  • Corey T. McMillan

  • Douglas Galasko

  • Jörg Hanrieder

  • Edward B. Lee

  • Hlin Kvartsberg

  • David J. Irwin

  • Kaj Blennow

  • June 24, 2026

  • 0 min

Share

Objective:

To evaluate the diagnostic performance of tau368 in distinguishing FTLD-tau from other neurodegenerative diseases using CSF biomarkers.

Approach:
  • Study Design: Examined tau368 immunoreactivity in postmortem hippocampus and frontal cortex sections from individuals with varying stages of AD pathology and selected non-AD neurodegenerative diseases.
  • Biomarker Analysis: Utilized tau368 immunofluorescence and luminescent conjugated oligothiophenes (LCOs) to compare tau368 staining and aggregate pathology.
  • CSF Biomarker Evaluation: Assessed CSF levels of p-tau181, p-tau212, tau368, t-tau, and their ratios to differentiate postmortem confirmed ADNC from other diseases.
Key Findings:
  • Tau368 showed stable levels across different neurodegenerative diseases.
  • The combination of tau368 with other tau biomarkers improved diagnostic performance for FTLD-tau.
  • CSF biomarker ratios involving tau368 provided better discrimination between AD and non-AD pathologies.
Interpretation:

Limitations:
  • The study was conducted on a rare autopsy cohort, which may limit generalizability.
  • Potential confounding factors from co-pathologies in AD cases were not fully addressed.
Conclusion:

Original Source(s)

Tau368 improves p-tau diagnostic accuracy for FTLD-tau from FTLD-TDP

  • by Przemysław R. Kac, Katheryn A. Q. Cousins, Alicja Szadziewska, Leslie M. Shaw, Michael Turton, Vivianna M. Van Deerlin, Peter Harrison, Henrik Zetterberg, David A. Wolk, Corey T. McMillan, Douglas Galasko, Jörg Hanrieder, Edward B. Lee, Hlin Kvartsberg, David J. Irwin, Kaj Blennow

  • June 24, 2026

Related Content

Oculomics: Beyond the Buzzword

Joseph J. Pizzimenti, OD, FAAO, FORS, discusses the capabilities of oculomics in retina and neuro-ophthalmology,

An intelligent gradient-guided hybrid inpainting framework for brain MRI reconstruction and Alzheimer's disease classification in connected healthcare systems

Comorbidity sequence, sex, and APOE-genotype forecast Alzheimer's disease diagnosis